Evidence map›Paper›PMID 33860132›Full record

ArticleJournal of the Endocrine Society2021

Long-term GH Therapy Does Not Advance Skeletal Maturation in Children and Adolescents.

Benjamin Udoka Nwosu, Gabrielle Jasmin, Sadichchha Parajuli, Alan D Rogol, Ellen Christine Wallace, Austin F Lee

Open access · goldAbstract read
In one paragraph

Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Benjamin Udoka NwosuDivision of Endocrinology, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA.ORCID https://orcid.org/0000-0003-2212-0276
Gabrielle JasminDivision of Endocrinology, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Sadichchha ParajuliDivision of Endocrinology, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Alan D RogolDivision of Endocrinology, Department of Pediatrics, University of Virginia, VA 22903, USA.ORCID https://orcid.org/0000-0002-7526-3142
Ellen Christine WallaceDivision of Radiology, Department of Pediatrics, University of Massachusetts, Worcester, MA 01655, USA.
Austin F LeeDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA 01655, USA.
University of Massachusetts Chan Medical School · USUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextThere is no consensus on the effect of recombinant human GH (rhGH) therapy on skeletal maturation in children despite the current practice of annual monitoring of skeletal maturation with bone age in children on rhGH therapy.

aimsTo investigate the effects of long-term rhGH therapy on skeletal age in children and explore the accuracy of bone age-predicted adult height (BAPAH) at different ages based on 13 years of longitudinal data.

methodsA retrospective longitudinal study of 71 subjects aged 2 to 16 years, mean 9.9 ± 3.8 years, treated with rhGH for nonsyndromic short stature for a duration of 2 to 14 years, mean, 5.5 ± 2.6 years. Subjects with syndromic short stature and systemic illnesses such as renal failure were excluded.

resultsBone age minus chronological age (BA-CA) did not differ significantly between baseline and the end of rhGH therapy (-1.05 ± 1.42 vs -0.69 ± 1.63,

conclusionLong-term rhGH therapy demonstrated an initial catch-up phenomenon in skeletal maturation in the first 6.5 years that plateaued thereafter with no overall significant advancement in bone age. These findings are reassuring and support strategic, but not the insurance company mandated reflexive annual monitoring of skeletal maturation with bone age in children receiving rhGH therapy.

Indexed as

bone agegrowth hormone deficiencyheight velocityshort stature

Identifiers

PMID33860132
PMCPMC8035984
OpenAlexW3135297157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.